Sensei Biotherapeutics

• Solnerstotug, a conditionally active monoclonal antibody targeting VISTA, showed a 14% overall response rate in PD-L1 resistant tumors, nearly triple the expected response rate for PD-L1 rechallenge. • Notable responses included a durable complete response in a Merkel cell carcinoma patient and a partial response in a microsatellite instability-high colorectal cancer patient who had previously progressed after checkpoint therapy. • The Phase 1/2 trial demonstrated a favorable safety profile with no dose-limiting toxicities, positioning solnerstotug as a potential new treatment option for patients with limited alternatives beyond chemotherapy.

• Sana Biotechnology's HIP-modified islet cells demonstrated immune evasion and C-peptide production in a Type 1 Diabetes patient without immunosuppression. • The positive Phase 1 data supports the potential of Sana's hypoimmune (HIP) cell platform, leading to increased price targets from analysts. • A single patient in the trial showed stable C-peptide levels 4 weeks post-injection, indicating the HIP cells' survival and function without triggering an immune response. • Sana Biotechnology's progress in Type 1 Diabetes treatment has been recognized, potentially setting a more favorable stage for its stock performance.